Preventing Visual Loss from Chronic Eye Disease in Primary Care: Scientific Review

JAMA

Volumn 291, Issue 12, 2004, Pages 1487-1496

  Rowe, Susannah ^a   MacLean, Catherine H ^b,c   Shekelle, Paul G ^b,d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RAND CORPORATION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; BLINDNESS; COCHRANE LIBRARY; DIABETES MELLITUS; EMBASE; EYE DISEASE; GLAUCOMA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; INJURY; MEDICAL LITERATURE; MEDLINE; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCREENING TEST; SYSTEMIC DISEASE; UNITED STATES; VISION TEST; VISUAL IMPAIRMENT; ADULT; CHRONIC DISEASE; GENERAL PRACTICE; SMOKING CESSATION; STANDARD;

ADULT; BLINDNESS; CHRONIC DISEASE; DIABETES MELLITUS; EYE DISEASES; FAMILY PRACTICE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; SMOKING CESSATION; VISION SCREENING;

EID: 1642353670     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.12.1487     Document Type: Review

References (122)

1. Friedman DS, Congdon N, Kempen J, Tielsch JM. Vision problems in the US prevalence of adult vision impairment and age-related eye disease in America. Available at: http://www.preventblindness.org/vpus /vp.html. Accessed February 24, 2004.
2. Rahmani B, Tielsch JM, Katz J, et al. The cause-specific prevalence of visual impairment in an urban population. Ophthalmology. 1996;103:1721-1726.
3. Tielsch JM, Javitt JC, Coleman A, et al. The prevalence of blindness and visual impairment among nursing home residents in Baltimore. N Engl J Med. 1995;332:1205-1209.
4. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med. 1991;325:1412-1417.
5. Javitt JC, McBean AM, Nicholson GA, et al. Undertreatment of glaucoma among black Americans. N Engl J Med. 1991;325:1418-1422.
6. Wang F, Ford D, Tielsch JM, et al. Undetected eye disease in a primary care clinic population. Arch Intern Med. 1994;154:1821-1828.
7. Leibowitz HM. Primary care: the red eye. N Engl J Med. 2000;343:345-351.
8. Shingleton BJ, O'Donoghue MW. Primary care: blurred vision. N Engl J Med. 2000;343:556-562.
9. Shingleton BJ. Eye injuries. N Engl J Med. 1991;325:408-413.
10. Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in tyge II diabetes over 6 years from diagnosis. Diabetologia. 2001;44:156-163.
11. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration. Ophthalmology. 2001;108:697-704.
12. Congdon NG. Prevention strategies for age related cataract. Br J Ophthalmol. 2001;85:516-520.
13. Preferred Practice Patterns: Diabetic Retinopathy. San Francisco, Calif: American Academy of Ophthalmology; 1998.
14. Primary Open Angle Glaucoma. San Francisco, Calif: American Academy of Ophthalmology; 2000.
15. Age-Related Macular Degeneration. San Francisco, Calif: American Academy of Ophthalmology; 2003.
16. Cataract In the Adult Eye. San Francisco, Calif: American Academy of Ophthalmology; 2001.
17. Refractive Error. San Francisco, Calif: American Academy of Ophthalmology; 1997.
18. Zadnik K, Satariano WA, Mutti DO, et al. The effect of parental history of myopia on children's eye size. JAMA. 1994;271:1323-1327.
19. Javitt JC, Wang F, West SK. Blindness due to cataract. Annu Rev Public Health. 1996;17:159-177.
20. Sims RV, Owsley C, Allman RM, et al. A preliminary assessment of the medical and functional factors associated with vehicle crashes by older adults. J Am Geriatr Soc. 1998;46:556-561.
21. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. JAMA. 1991;266:369-374.
22. Sommer A. Glaucoma risk factors observed in the Baltimore Eye Survey. Curr Opin Ophthalmol. 1996;7:93-98.
23. Katz J, Tielsch JM, Sommer A. Prevalence and risk factors for refractive errors in an adult inner city population. Invest Ophthalmol Vis Sci. 1997;38:334-340.
24. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997;38:83-91.
25. Salive ME, Guralnik J, Christen W, et al. Functional blindness and visual impairment in older adults from three communities. Ophthalmology. 1992;99:1840-1847.
26. West SK, Munoz B, Rubin GS, et al. Function and visual impairment in a population-based study of older adults. Invest Ophthalmol Vis Sci. 1997;38:72-82.
27. Chasan-Taber L, Willett WC, Seddon JM, et al. A prospective study of carotenoid and vitamin A intakes and risk of cataract extraction in US women. Am J Clin Nutr. 1999;70:509-516.
28. Klein R, Klein BE, Linton KL, De Mets DL. The Beaver Dam Eye Study: visual acuity. Ophthalmology. 1991;98:1310-1315.
29. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
30. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
31. Wake N, Hisashige A, Katayama T, et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes. Diabetes Res Clin Pract. 2000;48:201-210.
32. Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med. 1997;127:788-795.
33. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM, II: analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care. 1997;20:735-744.
34. Okamoto F, Sone H, Nonoyama T, Hommura S. Refractive changes in diabetic patients during intensive glycaemic control. Br J Ophthalmol 2000;84:1097-1102.
35. Eva PR, Pascoe PT, Vaughan DG. Refractive change in hyperglycaemia: hyperopia, not myopia. Br J Ophthalmol. 1982;66:500-505.
36. Gwinup G, Villarreal A. Relationship of serum glucose concentration to changes in refraction. Diabetes. 1976;25:29-31.
37. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36). BMJ. 2000;321:412-419.
38. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
39. Margulies LJ. Ocular manifestations of cardiovascular and hematologic disorders. Curr Opin Ophthalmol. 1995;6:97-103.
40. Talks SJ, Good P, Clough CG, et al. The acute and long-term ocular effects of accelerated hypertension. Eye. 1996;10:321-327.
41. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol. 1996;114:545-554.
42. Jakobiec FA, Albert D. Principles and Practice of Ophthalmology. Philadelphia, Pa: WB Saunders Co; 1999.
43. Recchia FM, Brown GC. Systemic disorders associated with retinal vascular occlusion. Curr Opin Ophthalmol. 2000;11:462-467.
44. Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol. 1994;117:603-624.
45. Guyer DR, Miller NR, Auer CL, Fine SL. The risk of cerebrovascular and cardiovascular disease in patients with anterior ischemic optic neuropathy. Arch Ophthalmol. 1985;103:1136-1142.
46. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. Ophthalmology. 2000;107:2224-2232.
47. Aiello LP, Cahill MT, Wong JS. Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol. 2001;132:760-776.
48. Klein R, Marino EK, Kuller LH, et al. The relation of atherosclerotic cardiovascular disease to retinopathy in people with diabetes in the Cardiovascular Health Study. Br J Ophthalmol. 2002;86:84-90.
49. Arroyo JG. Atherosclerotic cardiovascular disease and diabetic retinopathy. Br J Ophthalmol. 2002;86:3-4.
50. Maberley DA, King W, Cruess AF, Koushik A. Risk factors for diabetic retinopathy in the Cree of James Bay. Ophthalmic Epidemiol. 2002;9:153-167.
51. Ferris FL, Chew EY, Hoogwerf BJ. Serum lipids and diabetic retinopathy. Diabetes Care. 1996;19:1291-1293.
52. Guerci B, Meyer L, Sommer S, et al. Severity of diabetic retinopathy is linked to lipoprotein (a) in type 1 diabetic patients. Diabetes Metab. 1999;25:412-418.
53. Chew EY, Klein ML, Ferris FL, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Arch Ophthalmol. 1996;114:1079-1084.
54. Miki E, Lu M, Lee ET, et al. The incidence of visual impairment and its determinants in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44:S31-S36.
55. Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss. Invest Ophthalmol Vis Sci. 1998;39:233-252.
56. Klein BE, Klein R, Moss SE. Is serum cholesterol associated with progression of diabetic retinopathy or macular edema in persons with younger-onset diabetes of long duration? Am J Ophthalmol. 1999;128:652-654.
57. Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XlII: relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology. 1991;98:1261-1265.
58. Seddon JM, Rosner B, Sperduto RD, et al. Dietary fat and risk for advanced age-related macular degeneration. Arch Ophthalmol. 2001;119:1191-1199.
59. Cho E, Hung S, Willett WC, et al. Prospective study of dietary fat and the risk of age-related macular degeneration. Am J Clin Nutr. 2001;73:209-218.
60. Mares-Perlman JA, Brady WE, Klein R, et al. Dietary fat and age-related maculopathy. Arch Ophthalmol. 1995;113:743-748.
61. Heuberger RA, Mares-Perlman JA, Klein R, et al. Relationship of dietary fat to age-related maculopathy in the Third National Health and Nutrition Examination Survey. Arch Ophthalmol. 2001;119:1833-1838.
62. Vinger PF, Sachs BA. Ocular manifestations of hyperlipoproteinemia. Am J Ophthalmol. 1970;70:563-573.
63. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264-1268.
64. Salomon O, Huna-Baron R, Kurtz S, et al. Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 1999;106:739-742.
65. Guven D, Sayinalp N, Kalayci D, et al. Risk factors in central retinal vein occlusion and activated protein C resistance. Eur J Ophthalmol. 1999;9:43-48.
66. Klein BE, Klein R, Lee KE. Cardiovascular disease, selected cardiovascular disease risk factors, and age-related cataracts. Am J Ophthalmol. 1997;123:338-346.
67. The Eye Disease Case-control Study Group. Risk factors for branch retinal vein occlusion. Am J Ophthalmol. 1993;116:286-296.
68. Hagedoorn A. Cholesterol emboli. Arch Ophthalmol. 1966;76:604-605.
69. Cheng AC, Pang CP, Leung AT, et al. The association between cigarette smoking and ocular diseases. Hong Kong Med J. 2000;6:195-202.
70. Klein R, Klein BE, Moss SE. Relation of smoking to the incidence of age-related maculopathy: the Beaver Dam Eye Study. Am J Epidemiol. 1998;147:103-110.
71. West S, Munoz B, Emmett EA, Taylor HR. Cigarette smoking and risk of nuclear cataracts. Arch Ophthalmol. 1989;107:1166-1169.
72. Weintraub JM, Willett WC, Rosner B, et al. Smoking cessation and risk of cataract extraction among US women and men. Am J Epidemiol. 2002;155:72-79.
73. Christen WG, Glynn RJ, Ajani UA, et al. Smoking cessation and risk of age-related cataract in men. JAMA. 2000;284:713-716.
74. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105:998-1003.
75. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association: clinical practice recommendations 2002. Diabetes Care. 2002;25:S1-S147.
76. Bertelsen JB, Hegedus L. Cigarette smoking and the thyroid. Thyroid. 1994;4:327-331.
77. Tallstedt L, Lundell G, Taube A. Graves' ophthalmopathy and tobacco smoking. Acta Endocrinologica. 1993;129:147-150.
78. Winsa B, Mandahl A, Karlsson FA. Graves' disease, endocrine ophthalmopathy and smoking. Acta Endocrinologica. 1993;128:156-160.
79. Bartalena L, Martino E, Marcocci C, et al. More on smoking habits and Graves' ophthalmopathy. J Endocrinol Invest. 1989;12:733-737.
80. Mann K. Risk of smoking in thyroid-associated orbitopathy. Exp Clin Endocrinol. 1999;107(suppl): S164-S167.
81. Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. JAMA. 1993;269:479-482.
82. Trobe J. The Physician's Guide to Eye Care. 2nd ed. San Francisco, Calif: American Academy of Ophthalmology; 2001.
83. American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Available at: http://www.aao.org/aao/education/library/information /loader.cfm?url=/commonspot/security/getfile .cfm&PageID=25029. Accessed February 24, 2004:
84. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol. 2001;119:1417-1436.
85. Sandstead HH. Requirements and toxicity of essential trace elements, illustrated by zinc and copper. Am J Clin Nutr. 1998;61;621S-624S.
86. Lotan R. Lung cancer promotion by beta-carotene and tobacco smoke. J Natl Cancer Inst. 1999;91:7-9.
87. Paolini M, Cantelli-Forti G, Perocco P, et al. Cocarcinogenic effect of beta-carotene. Nature. 1999;398:760-761.
88. Hiller R, Sperduto RD, Ederer F. Epidemiologic associations with cataract in the 1971-1972 National Health and Nutrition Examination Survey. Am J Epidemiol. 1983;118:239-249.
89. Cruickshanks KJ, Klein BE, Klein R. Ultraviolet light exposure and lens opacities: the Beaver Dam Eye Study. Am J Public Health. 1992;82:1658-1662.
90. Taylor HR. Ultraviolet radiation and the eye. Trans Am Ophthalmol Soc 1989;87:802-853.
91. McCarty CA, Mukesh BN, Fu CL, Taylor HR. The epidemiology of cataract in Australia. Am J Ophthalmol. 1999;128:446-465.
92. West S. Ocular ultraviolet 8 exposure and lens opacities: a review. J Epidemiol. 1999;9:S97-S101.
93. Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy. Diabetes Care. 1998;21:143-156.
94. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med. 1996;124:164-169.
95. Viian S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA. 2000;283:889-896.
96. American Optometric Association. Optometric Clinical Practice Guideline: care of the patient with diabetes mellitus: reference guide for clinicians, third revision, 2002. Available at: http://www.aoa.org/eweb/Documents/CPG-3.pdf. Accessed February 25, 2004.
97. American Diabetes Association. Position statement: diabetic retinopathy. Diabetes Care. 1929;25: S90-S93.
98. National Guideline Clearinghouse. Guideline title: the management of diabetes mellitus in the primary care setting. Available at: http://www.guideline.gov /summary/summary.aspx?doc_id=2583&nbr =1809&string=diabetes+AND+mellitus. Accessed February 25, 2004.
99. Javitt JC. How often should patients with diabetes be screened for retinopathy? JAMA. 2000;284:437-438; discussion 439.
100. Fong DS, Gottlieb J, Ferris FL3, Klein R. Understanding the value of diabetic retinopathy screening. Arch Ophthalmol. 2001;119:758-760.
101. American Association of Clinical Endocrinologists. Diabetes guidelines. Endocr Pract. 2002;8 (suppl 1):40-82.
102. Canadian Task Force on the Periodic Health Examination. Periodic health examination, 1995 update, 3: screening for visual problems among eldedy patients. CMAJ. 1995;152:1211-1222.
103. International Diabetes Center. Type 2 Diabetes Practice Guidelines. Minneapolis, Minn: International Diabetes Center, 2001.
104. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, X: four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol. 1989;107:244-249.
105. KJein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of diabetic retinopathy, XIV: ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol. 1994;112:1217-1228.
106. The Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. Diabetes Care. 2000;23:1084-1091.
107. National Committee for Quality Assurance. Diabetes quality improvement project initial measure set (final version). Available at: http://www.ncqa.org/dprp/dqip2.htm#synopsis. Accessed February 17, 2004.
108. Singer DE, Nathan DM, Fogel HA, Schachat AP. Screening for diabetic retinopathy. Ann Intern Med. 1992;116:660-671.
109. Eady Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. Ophthalmology. 1991;98:823-833.
110. Klein R, Klein BE, Neider MW, et al. Diabetic retinopathy as detected using ophthalmoscopy, a non-mydriatic camera and a standard fundus camera. Ophthalmology. 1988;92:485-491.
111. Moss SE, Klein R, Kessler SD, Richie KA. Comparison between ophthalmoscopy and fundus photography in determining severity of diabetic retinopathy. Ophthalmology. 1985;92:62-67.
112. Stellingwerf C, Hardus PL, Hooymans JM. Two-field photography can identify patients with vision-threatening diabetic retinopathy. Diabetes Care. 2001;24:2086-2090.
113. Bursell SE, Cavallerano JD, Cavallerano AA, et al, for Joslin Vision Network Research Team. Stereo nonmydriatic digital-video color retinal imaging compared with Early Treatment Diabetic Refinopathy Study seven standard field 35-mm stereo color photos for determining level of diabetic retinopathy. Ophthalmology. 2001;108:572-585.
114. Lee SC, Lee ET, Kingsley RM, et al. Comparison of diagnosis of early retinal lesions of diabetic retinopathy between a computer system and human experts. Arch Ophthalmol. 2001;119:509-515.
115. Smeeth L, Iliffe S. Community screening for visual impairment in the eldedy. Cochrane Database Syst Rev [serial online]. 2003;1:CD001084.
116. United States Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd Edition: Screening for Visual Impairment. Baltimore, Md: Williams & Wilkins; 1996.
117. American Academy of Family Physicians. Summary of AAFP Policy Recommendations for Periodic Health Examination Revision 5.1. Kansas City, Mo: American Academy of Family Physicians; 2001.
118. National Eye Institute, National Institutes of Health. NEI statement: vision screening in adults. Available at: http://www.nei.nih.gov/news/statements/vis%2Dscreen.htm. Accessed February 17, 2004.
119. American Optometric Association Consensus Panel on Comprehensive Adult Eye and Vision Examination. Comprehensive adult eye and vision evaluation. Available at: http://www.aoa.org/conditions /issues-guidelines.asp. Accessed February 24, 2004.
120. Institute for Clinical Systems Improvement. Health care guidelines: preventive services for adults. Available at: http://www.icsi.org/index.asp. Accessed February 24, 2004.
121. Department of Veterans Affairs. Screening for Glaucoma in the Primary Care Setting. Washington, DC: Department of Veterans Affairs; 2000.
122. American Academy of Ophthalmology. Comprehensive Adult Medical Eye Evaluation. San Francisco, Calif: American Academy of Ophthalmology; 2000.